In one paragraphArticle in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Daniel Guimarães TiezziLaboratory for Translational Data Science, Breast Disease Division, Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14048-900, Brazil.ORCID 0000-0002-2660-0093 Isabela Panzeri Carlotti BuzattoLaboratory for Translational Data Science, Breast Disease Division, Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14048-900, Brazil.
Willian Abraham da SilveiraSchool of Science, Engineering and Environment, University of Salford, Salford M5 4WT, UK.
Anna Clara MontiDipartimento di Diritto, Economia, Management e Metodi Quantitativi, Università degli Studi del Sannio, 82100 Benevento, Italy.ORCID 0000-0003-3369-884X Fabiana de Oliveira BuonoLaboratory for Translational Data Science, Breast Disease Division, Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14048-900, Brazil.
Juliana MeolaLaboratory for Translational Data Science, Breast Disease Division, Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14048-900, Brazil.ORCID 0000-0003-2514-4011 Omero Benedicto Poli-NetoLaboratory for Translational Data Science, Breast Disease Division, Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14048-900, Brazil.ORCID 0000-0003-0270-5496 Stefano Maria PagnottaDipartimento di Scienze e Tecnologie, Università degli Studi del Sannio, 82100 Benevento, Italy.ORCID 0000-0002-8298-9777 Funding
Coordination for the Improvement of Higher Education Personnel (CAPES) and National Council for Scientific and Technological Development (CNPq) 88887.887707/2023-00 and 309401/2021-6
6 · The paper itselfAbstract
The cHER2+ breast cancer subtype is characterized by the overexpression of the HER2 oncoprotein based on immunohistochemistry (IHC)/or by
Indexed as
Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorFemaleGene AmplificationGene Expression Regulation, NeoplasticHumansMolecular Targeted TherapyNeoadjuvant TherapyPrognosisBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine Kinasesbreast cancermolecular profilepredictive factorstargeted therapy
Identifiers
PMID41465240
PMCPMC12732813
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390